Accès gratuit
Med Sci (Paris)
Volume 29, Numéro 2, Février 2013
Page(s) 165 - 173
Section M/S Revues
Publié en ligne 28 février 2013
  1. Dock G. The influence of complicating diseases upon leukemia. Am J Med Sci 1904 ; 127 : 563–592. [CrossRef] [Google Scholar]
  2. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther ; 15 : 651–659. [CrossRef] [PubMed] [Google Scholar]
  3. Sinkovics JG, Horvath JC. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp 2008 ; 56 Suppl 1 : 3s–59s. [CrossRef] [Google Scholar]
  4. Asada T. Treatment of human cancer with mumps virus. Cancer 1974 ; 34 : 1907–1928. [CrossRef] [PubMed] [Google Scholar]
  5. Breitbach CJ, Paterson JM, Lemay CG, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007 ; 15 : 1686–1693. [CrossRef] [PubMed] [Google Scholar]
  6. Stanford MM, Breitbach CJ, Bell JC, McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther 2008 ; 10 : 32–37. [PubMed] [Google Scholar]
  7. Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007 ; 28 : 42–58. [CrossRef] [PubMed] [Google Scholar]
  8. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000 ; 6 : 821–825. [CrossRef] [PubMed] [Google Scholar]
  9. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003 ; 4 : 263–275. [CrossRef] [PubMed] [Google Scholar]
  10. Whitman ED, Tsung K, Paxson J, Norton JA. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery 1994 ; 116 : 183–188. [PubMed] [Google Scholar]
  11. Gnant MF, Puhlmann M, Alexander HR, Jr., Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res 1999 ; 59 : 3396–3403. [PubMed] [Google Scholar]
  12. Brun J, McManus D, Lefebvre C, et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther 2010 ; 18 : 40–49. [CrossRef] [Google Scholar]
  13. Thorne SH, Hwang TH, O’Gorman WE, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007 ; 117 : 3350–3358. [CrossRef] [PubMed] [Google Scholar]
  14. Naik S, Nace R, Barber GN, Russell SJ. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther 2012 ; 19 : 443–450. [CrossRef] [PubMed] [Google Scholar]
  15. Zamarin D, Martinez-Sobrido L, Kelly K, et al. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 2009 ; 17 : 697–706. [CrossRef] [PubMed] [Google Scholar]
  16. Kirn DH, Wang Y, Liang W, et al. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 2008 ; 68 : 2071–2075. [CrossRef] [PubMed] [Google Scholar]
  17. Jin J, Liu H, Yang C, et al. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Mol Cancer Ther 2009 ; 8 : 1387–1397. [CrossRef] [PubMed] [Google Scholar]
  18. Ungerechts G, Springfeld C, Frenzke ME, et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007 ; 67 : 10939–10947. [CrossRef] [PubMed] [Google Scholar]
  19. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004 ; 103 : 1641–1646. [CrossRef] [PubMed] [Google Scholar]
  20. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010 ; 18 : 1155–1164. [CrossRef] [PubMed] [Google Scholar]
  21. Pol J, Rességuier J, Lichty B. Oncolytic viruses: a step into cancer immunotherapy. Virus Adaptation and Treatment 2012 ; 4 : 1–21. [Google Scholar]
  22. Lee JH, Roh MS, Lee YK, et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther 2009 ; 17 : 73–79. [PubMed] [Google Scholar]
  23. Lei N, Shen FB, Chang JH, et al. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther 2009 ; 16 : 33–43. [CrossRef] [PubMed] [Google Scholar]
  24. Kaur B, Cripe TP, Chiocca EA. “Buy one get one free”: armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 2009 ; 9 : 341–355. [CrossRef] [PubMed] [Google Scholar]
  25. Jarnagin WR, Zager JS, Klimstra D, et al. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther 2003 ; 10 : 215–223. [CrossRef] [PubMed] [Google Scholar]
  26. Wong RJ, Chan MK, Yu Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004 ; 10 : 251–259. [CrossRef] [PubMed] [Google Scholar]
  27. Varghese S, Rabkin SD, Liu R, et al. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 2006 ; 13 : 253–265. [CrossRef] [PubMed] [Google Scholar]
  28. Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000 ; 97 : 2208–2213. [CrossRef] [Google Scholar]
  29. Huang JH, Zhang SN, Choi KJ, et al. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4–1BBL. Mol Ther 2010 ; 18 : 264–274. [CrossRef] [PubMed] [Google Scholar]
  30. Fukuhara H, Ino Y, Kuroda T, et al. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7–1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 2005 ; 65 : 10663–10668. [CrossRef] [PubMed] [Google Scholar]
  31. Bridle BW, Stephenson KB, Boudreau JE, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010 ; 184 : 4269–4275. [Google Scholar]
  32. Castelo-Branco P, Passer BJ, Buhrman JS, et al. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther 2010 ; 17 : 805–810. [CrossRef] [PubMed] [Google Scholar]
  33. Ottolino-Perry K, Diallo JS, Lichty BD, et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010 ; 18 : 251–263. [CrossRef] [PubMed] [Google Scholar]
  34. Le Boeuf F, Diallo JS, McCart JA, et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 2010 ; 18 : 888–895. [CrossRef] [PubMed] [Google Scholar]
  35. Nguyen TL, Wilson MG, Hiscott J. Oncolytic viruses and histone deacetylase inhibitors-a multi-pronged strategy to target tumor cells. Cytokine Growth Factor Rev 2010 ; 21 : 153–159. [CrossRef] [PubMed] [Google Scholar]
  36. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999 ; 5 : 881–887. [CrossRef] [PubMed] [Google Scholar]
  37. Diallo JS, Le Bœuf F, Lai F, et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther 2010 ; 18 : 1123–1129. [CrossRef] [PubMed] [Google Scholar]
  38. Passer BJ, Cheema T, Zhou B, et al. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res 2010 ; 70 : 3890–3895. [CrossRef] [PubMed] [Google Scholar]
  39. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012 ; 30 : 658–670. [CrossRef] [PubMed] [Google Scholar]
  40. Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011 ; 477 : 99–102. [CrossRef] [PubMed] [Google Scholar]
  41. Touchefeu Y, Schick U, Harrington KJ. Le virus de la rougeole - Un futur traitement en cancérologie? Med Sci (Paris) 2012 ; 28 : 388–394. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  42. Lemay G. Apprivoiser nos ennemis pour en faire des alliés : la « virothérapie » anticancéreuse. Med Sci (Paris) 2012 ; 28 : 339–340. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  43. Janelle V, Poliquin L, Lamarre A. Le virus de la stomatite vésiculaire dans la lutte contre le cancer. Med Sci (Paris) 2013, 29 : 175–182. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.